Latest for Vivace Therapeutics

In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.

With $30 million in Series C financing, Vivace is aiming to test one of its candidates against that pathway starting in early 2021.